As you can see, this profile has shown the ability to make triple-digit moves in the short term.
Here are some examples:
#1. On March 12th, VICA surged from an open of $.045 to a high of $.12. That move proved VICA an intraday mover of 166%.
#2. From a low on March 31st of $.109 to a high of $.265 on April 1st, VICA surged 143%.
#3. On April 22nd, VICA rocketed from an open of $.182 to a high of $.3799. Moving approximately 108% intraday, VICA once again showed its breakout potential.
See what I mean?
Your No. 2 Potential Driver Indicator - Bounce/Reversal Possibilities
As you can see in the chart above, VICA has been in a bit of a downtrend. Sometimes after a downtrend, a healthy reversal can begin.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
As of 11:00PM Thursday, VICA was displaying multiple oversold leaning technicals that could be signaling an upcoming bounce.
Here are a few to keep a close eye on (reported by Barchart):
- 9-Day Relative Strength Index: 39.89%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 9.95%
- 14-Day Williams %R: 90.05%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Your No. 3 Potential Driver Indicator - Major Acquisition Of C-Pharm
Rafina Innovations Inc. Acquires C-Pharm Ltd Pharmaceutical
Nicosia, Cyprus, April 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Rafina Innovations Inc. (OTC PINK: VICA), a Medical and Pharmaceutical development company, today announced the 100% acquisition of C-Pharm Ltd, an established wholesale licensed pharmaceutical company that trades products in the Euro-Asia territories.
Constantinos Zertalis, Rafina’s Chairman, President and CEO, commented: "I am very excited to announce the closing of this acquisition and to have C-Pharm’s talented team become part of Rafina."
C-Pharm holds a wholesale license for medicinal products for human use. The scope of the license includes the import and export of Active Pharmaceutical Ingredients (API). This license allows also to trade pharmaceutical products to wholesalers and manufacturers all over the world and to support with medical consumables Cruise Ships and merchant vessels.
C-Pharm has undertaken exclusivities on behalf of pharmaceutical companies that produce medicines in Greece on the finding, control, technical chemical testing, purchase, transport, and delivery of API products. Imports are made with strict transport and storage protocol procedures, accompanied with data loggers for monitoring conditions of assets during transportation.
Rafina plans to introduce additional funding to the C-Pharm subsidiary to expand operations and win larger contracts within the region, while simultaneously increasing purchasing power to reduce the purchase costs from manufacturers by 10-20%.
Current C-Pharm clients are purely providing Pharmaceutical products in the Greek territories and Rafina plans to expand those opportunities outside of Greece in the near future.
Read the full article here.
Your No. 4 Potential Driver Indicator - C-Pharm Announces Big Revenue
Rafina's Subsidiary C-Pharm Ltd Revenues for First Quarter 2021 $1.7Mn
Nicosia, Cyprus, May 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Rafina Innovations Inc. (OTC PINK: VICA), a Medical and Pharmaceutical development company, is pleased to announce C-Pharm's 1st Quarter -31 March, 2021- revenues for 2021 are $1.7Mn US dollars.
Rafina's CEO stated, "Over a year into the pandemic, C-Pharm managed to increase its revenues from $700k within the first quarter of 2020 to $1.7Mn in the first quarter of 2021, by acquiring new business strategies, expanding in new territories and creating new opportunities during difficult times. We have significantly increased our distribution and sale in pharmaceutical products throughout Europe. The next goal is to expand further into the Europe – Asia territories."
C-Pharm's unique business model allows Rafina to introduce its other suite of products to existing C-Pharm customers and industries. This is a massive opportunity for Rafina Innovations, Inc. to expand its businesses and create a global hub for medical supplies in addition to PPE and other related products and companies.
Read the full article here.
Your No. 5 Potential Driver Indicator - New Website/Exclusive Distributor Agreement
Rafina Innovations Inc. Announces Brand-New Website and Exclusive Distributor Agreement with OPTEC International Inc.
Nicosia, Cyprus, May 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Rafina Innovations Inc. (OTC PINK: VICA), a Medical and Pharmaceutical development company, is pleased to officially announce the launch of its brand-new website and domain, designed with a user-friendly navigation, updated with the latest information and topics about its products and services. Its company goal with the new website is to provide its customers and shareholders an easier way to learn about the company. Rafina’s team will be constantly updating the company’s content with helpful information, articles and company announcements.
Rafina Innovations Inc. is pleased to announce that it has entered into an Exclusive Distribution Agreement with OPTEC International, Inc., a developer of UV and UV-C safety products using related advanced technologies specific to Personal Protection Equipment (PPE), and supplier of wholesale Medical PPE, for Cyprus. Rafina will enjoy an exclusive right to distribute all OPTEC product lines.
Constantinos Zertalis, Rafina’s Chairman, President and CEO, commented: "We at Rafina Innovations, Inc. are excited to announce the launch of our Brand-New Website and the signing of the Exclusive Distribution Agreement with OPTEC International which will definitely help us to increase sales and will have a positive impact on our revenue streams that will help the company to go to the next level.”
OPTEC International CEO, Roger Pawson, stated: “We are very happy to have Rafina as an exclusive distributor for the Cyprus territory to expand our product lines to this medical/pharmaceutical region and particularly in the Ocean-Going Vessel Shipping sectors. We look forward to further expanding our cooperation with Rafina in this region.”
Read the full article here.
Your VICA Potential Driver Indicator Recap - What To Know
#1. Low Float Profile - 4.4Mn Shares
#2. Healthy Reversal/Bounce Potential
#3. Major Acquisition Of C-Pharm
#4. C-Pharm Announces Big Revenue
#5. New Website/Exclusive Distributor Agreement
Coverage is officially initiated on VICA. While you have time, do this now: